- Home
- PCRX vs FRPH Comparison
PCRX vs FRPH Comparison
Compare PCRX & FRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- FRPH
- Stock Information
- Founded
- PCRX 2006
- FRPH 1986
- Country
- PCRX United States
- FRPH United States
- Employees
- PCRX N/A
- FRPH N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- FRPH Real Estate
- Sector
- PCRX Health Care
- FRPH Finance
- Exchange
- PCRX Nasdaq
- FRPH Nasdaq
- Market Cap
- PCRX 1.2B
- FRPH 459.4M
- IPO Year
- PCRX 2011
- FRPH N/A
- Fundamental
- Price
- PCRX $21.38
- FRPH $23.70
- Analyst Decision
- PCRX Buy
- FRPH
- Analyst Count
- PCRX 5
- FRPH 0
- Target Price
- PCRX $32.40
- FRPH N/A
- AVG Volume (30 Days)
- PCRX 531.5K
- FRPH 57.7K
- Earning Date
- PCRX 11-06-2025
- FRPH 11-05-2025
- Dividend Yield
- PCRX N/A
- FRPH N/A
- EPS Growth
- PCRX N/A
- FRPH N/A
- EPS
- PCRX N/A
- FRPH 0.28
- Revenue
- PCRX $705,848,000.00
- FRPH $32,293,999.00
- Revenue This Year
- PCRX $7.27
- FRPH N/A
- Revenue Next Year
- PCRX $10.18
- FRPH N/A
- P/E Ratio
- PCRX N/A
- FRPH $84.65
- Revenue Growth
- PCRX 2.25
- FRPH 3.18
- 52 Week Low
- PCRX $16.00
- FRPH $22.95
- 52 Week High
- PCRX $27.64
- FRPH $33.00
- Technical
- Relative Strength Index (RSI)
- PCRX 34.61
- FRPH 40.38
- Support Level
- PCRX $20.84
- FRPH $22.95
- Resistance Level
- PCRX $21.90
- FRPH $24.80
- Average True Range (ATR)
- PCRX 0.86
- FRPH 0.63
- MACD
- PCRX -0.03
- FRPH -0.12
- Stochastic Oscillator
- PCRX 41.56
- FRPH 28.85
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).